Tag

Renal Cell Carcinoma

All articles tagged with #renal cell carcinoma

music19 days ago•19 min saved

Brad Arnold’s Passing Closes a turbulent chapter for 3 Doors Down

Brad Arnold, the frontman of 3 Doors Down, died at 47 after a battle with stage IV kidney cancer (renal cell carcinoma). The piece recalls his warm, unifying presence, the band’s ascent to multi-platinum success with The Better Life, and a string of tragedies the group endured—bassist Todd Harrell’s vehicular homicide conviction and later prison time (2013–2015) and guitarist Matt Roberts’ overdose (2016)—as Arnold fought sobriety and cancer. It notes his faith, conservative leanings, and public support for troops, including appearances at the USO and Trump-era events, and it collects tributes from peers who remembered him as a connector who valued fans above all.

via Rolling Stone|

#3-doors-down #brad-arnold #music

health2 years ago•45 min saved

KEYTRUDA® Shows Promising Results as Adjuvant Therapy for Renal Cell Carcinoma Patients

Merck's anti-PD-1 therapy, KEYTRUDA, has shown a statistically significant improvement in overall survival (OS) as adjuvant therapy for patients with renal cell carcinoma (RCC) at intermediate-high or high risk of recurrence following nephrectomy, according to the Phase 3 KEYNOTE-564 trial. This marks the first time a therapy has demonstrated a survival benefit compared to placebo in this patient population. The results build on the previously reported disease-free survival benefit from the same trial. KEYTRUDA's safety profile was consistent with previous studies, and the results will be presented at an upcoming medical meeting and submitted to regulatory authorities.

via Merck|

#adjuvant-therapy #clinical-trial #health

health2 years ago•10 min saved

Merck's WELIREG® Phase 3 Trial Shows Promising Results in Advanced Renal Cell Carcinoma

Merck has announced positive Phase 3 trial results for WELIREG (belzutifan), its oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor, in the treatment of advanced renal cell carcinoma (RCC) that has progressed following PD-1/L1 checkpoint inhibitor and vascular endothelial growth factor-tyrosine kinase inhibitor (VEGF-TKI) therapies. The trial showed statistically significant improvements in progression-free survival (PFS) compared to everolimus, as well as a significant improvement in objective response rate (ORR). While there was a trend towards improvement in overall survival (OS), it did not reach statistical significance. The safety profile of WELIREG was consistent with previous studies.

via Merck|

#health #merck #phase-3-trial